Bioactive Products
| Cat. No. | Information |
| CFN97207 | Specioside Specioside has antioxidant, analgesic, anti-dyspeptic, astringent, liver stimulating and wound healing activities. It ameliorates oxidative stress and promotes longevity in Caenorhabditis elegans. |
| CFN97236 | Usnic acid Usnic acid has antitumoral, acaricidal, larvicidal, antiviral, antibiotic, antipyretic, analgesic,gastroprotective, antioxidative and anti-inflammatory activities. Use of reconstituted bovine type-I collagen-based films containing usnic acid can improve burn healing process in rats. Usnic acid perturbs various interrelated signaling pathways and that autophagy induction is a defensive mechanism against usnic acid-induced cytotoxicity; it disturbs calcium homeostasis, induces ER stress, and that Usnic acid-induced cellular damage occurs at least partially via activation of the Ca(2+) channel of SOCE. |
| CFN97764 | Deoxyelephantopin Deoxyelephantopin has anti-inflammatory, hepatoprotective, and wound healing activities; it also has antitumor activity, by inhibiting metastatic, inducing apoptosis, modulating oxidative stress , STAT3/p53/p21 signaling, MAPK pathway, PI3k/Akt/mTOR pathway, caspase cascades, and ROS . |
| CFN90486 | Dracorhodin perchlorate Dracorhodin perchlorate inhibits cell growth, and induces apoptosis in fibroblasts in a dose-and time-dependent manner, arresting cell cycle at G1 phase, may as a candidate for anti-breast cancer. Dracorhodin perchlorate can inhibit high glucose-induced serum and glucocorticoid induced protein kinase 1 (SGK1) and fibronectin(FN) expression in human mesangial cells, and this may be part of the mechanism of preventing and treating renal fibrosis of DN. |
| CFN92024 | Deoxyshikonin Deoxyshikonin and dodecyl gallate show significantly synergic antimicrobial activity with penicillin in vivo and in vitro, and can effectively reduce nasopharyngeal and lung colonization caused by different penicillin-resistant pneumococcal serotypes. Deoxyshikonin exerts very good radical scavenging activities toward ABTS+ but shows moderate inhibition of DPPH·, and shows cytotoxic activities. Deoxyshikonin may be a new drug candidate for wound healing and treatment of lymphatic diseases. |
